Impact of an e-Bug Educational Intervention on HPV Vaccine Uptake in Middle School Students
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Consent for HPV vaccination.
- Who it may be relevant to
- Registry conditions: Papillomavirus Infection, Papillomavirus Vaccines, Vaccination Coveage. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pilot Observational Comparative Study Evaluating the Impact of the e-Bug Educational Programme on Parental Consent and HPV Vaccination Coverage During the National School-Based Vaccination Campaign in a Middle School in the Alpes-Maritimes
Overview
This study is a non-interventional observational pilot analysis assessing the possible impact of an educational programme (e-Bug) on parental consent and HPV vaccination uptake during the 2023-2024 and 2024-2025 national school-based HPV vaccination campaigns in France. The study focuses on one middle school in the Alpes-Maritimes department where teachers and the school nurse had been previously trained on HPV and used e-Bug educational resources in class as part of routine health education. No research-related intervention was conducted, and the educational programme was not introduced or modified for the purpose of the study. Only aggregated and anonymised vaccination data were used. These data were routinely collected by the Regional Health Agency (ARS PACA) as part of the national vaccination programme and transmitted for analysis. Aggregated data from the pilot school were compared with departmental-level outcomes to describe whether an upstream educational approach may be associated with improved parental acceptance and higher HPV vaccination coverage. This study aims to contribute to the understanding of educational determinants of vaccine uptake in a real-life school setting without involving any participant recruitment or individual data collection.
Interventions
- Other Consent for HPV vaccination
Consent for HPV vaccination
Primary outcome measures
- HPV vaccination uptake (1st and 2nd doses) in the pilot school compared with departmental data [Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)]
Secondary outcome measures (2)
- Parental consent rate (acceptability) [Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)]
- Response rate (return of vaccination authorisation forms) [Time frame: From (start of 2023-2024 HPV vaccination campaign) to(end of 2024-2025)]
Eligibility criteria
Inclusion criteria
- No individual participants are enrolled. The study uses only aggregated, anonymised vaccination data routinely collected by ARS PACA
Exclusion criteria
- Not applicable. No individual-level inclusion or exclusion criteria are defined, as no participants are enrolled.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Ecologic or community
Study locations
France · 1 center
- CHU de NICE — Nice
Identifiers
NCT: NCT07266857 · 25SantéMentale02